为了满足对降胆固醇药物的需求, 阳光生物制药公司在加拿大推出通用普拉瓦斯塔丁. Sunshine Biopharma launches generic pravastatin in Canada to address rising demand for cholesterol-lowering drugs.

Sunshine Biopharma通过其加拿大单位Nora Pharma推出了一种普通版的pravastatin,这是一种用于降低LDL胆固醇并减少心脏病发作和中风风险的Stain药物。 Sunshine Biopharma, via its Canadian unit Nora Pharma, has launched a generic version of pravastatin, a statin drug used to lower LDL cholesterol and reduce heart attack and stroke risk. 该药物可用10毫克、20毫克和40毫克剂量,这是对脂质减低疗法日益增长的需求的一部分。 Available in 10 mg, 20 mg, and 40 mg doses, the medication is part of growing demand for lipid-lowering therapies. 加拿大的此类药物市场预计到2025年将达到5.82亿美元,到2033年将增长到10.7亿美元,届时全球需求将超过465.8亿美元。 The Canadian market for such drugs is projected to reach $582 million by 2025 and grow to $1.07 billion by 2033, with global demand exceeding $46.58 billion by then. 该公司现在在加拿大提供74种非专利药物,计划在2026年提供更多,并正在推进肝癌和抗病毒治疗的研究。 The company now offers 74 generic drugs in Canada, with more planned for 2026, and is advancing research in liver cancer and antiviral treatments.